Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

SS-31 vs MOTS-C: Quick Comparison Overview

Type Synthetic tetrapeptide Mitochondria-derived peptide (MDPs) Sequence D-Arg-Dmt-Lys-Phe-NH2 MRWQEMGYIFYPRKLR Target Mitochondrial inner membrane Cytoplasmic/nuclear (retrograde signal) FDA status Approved for Barth syndrome (2023) Not approved Key research

This comparison does not assign a generated winner or score.

  • Type
  • Synthetic tetrapeptide
  • Mitochondria-derived peptide (MDPs)
  • Sequence
  • D-Arg-Dmt-Lys-Phe-NH2
  • MRWQEMGYIFYPRKLR
  • Target
  • Mitochondrial inner membrane
  • Cytoplasmic/nuclear (retrograde signal)
  • FDA status
  • Approved for Barth syndrome (2023)
  • Not approved
  • Key research
  • Barth syndrome, heart failure, aging
  • Exercise mimetic, fat oxidation, aging
  • Administration
  • Subcutaneous daily
  • Subcutaneous (various protocols)
  • PSPeptides
  • Coming soon
  • From $69.99
More references

Related material

Comparison

SS-31 vs MOTS-C: How SS-31 Works

In the SS-31 vs MOTS-C comparison, SS-31’s mechanism is structural: the peptide (sequence: D-Arg-Dmt-Lys-Phe-NH2) selectively concentrates 1,000–5,000× within the inner mitochondr…

View details →
Comparison

SS-31 vs MOTS-C: How MOTS-C Works

MOTS-C’s mechanism in the SS-31 vs MOTS-C comparison is metabolic signaling rather than structural protection. MOTS-C is encoded within the mitochondrial 12S rRNA gene — making it…

View details →